XML 63 R46.htm IDEA: XBRL DOCUMENT
v3.19.1

Collaboration and License Agreements - Additional Information (Details) - USD ($) $ in Thousands |  |  |  |  |  |  |  | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | ---
Oct. 11, 2017 | May 25, 2017 | Feb. 24, 2017 | Aug. 10, 2016 | Oct. 30, 2015 | Sep. 04, 2014 | Sep. 11, 2006 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Shares issued under license agreement |  | 8,799 |  |  |  | 13,199 |  |  |  |  |
Research and development |  |  |  |  |  |  |  | $ 8,767 | $ 6,067 |  |
Memorial Sloan Kettering Cancer Center |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Upfront license fees |  |  |  |  |  |  |  | 300 |  |  |
Minimum annual royalty payment |  |  |  |  |  | $ 100 |  | 100 | 100 |  |
Research funding costs |  |  |  |  |  |  |  | 100 | 200 | $ 200 | $ 200
Milestone payments |  | $ 200 |  |  |  | $ 17,400 |  | 500 | 700 |  |
License agreement expiration term |  |  |  |  |  | 10 years |  |  |  |  |
Milestone fee payments upon commencement of clinical trials |  | $ 300 |  |  |  |  |  |  |  |  |
License agreement outstanding amount payable |  |  |  |  |  |  |  | 1,000 | $ 1,000 |  |
License Agreement Terms | Memorial Sloan Kettering Cancer Center |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Percentage of fully diluted share capital |  |  |  |  |  | 1.50% |  |  |  |  |
Upfront license fees |  |  |  |  |  | $ 1,300 |  |  |  |  |
Memorial Sloan Kettering Cancer Center Amended And Restated License Agreement |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Shares issued under license agreement |  | 15,399 |  |  |  |  |  |  |  |  |
Memorial Sloan Kettering Cancer Center Amended And Restated License Agreement | Memorial Sloan Kettering Cancer Center |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Milestone fee payments upon commencement of clinical trials |  | $ 400 |  |  |  |  |  |  |  |  |
First MSK Amendment | Memorial Sloan Kettering Cancer Center |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Shares issued under license agreement |  |  |  |  | 10,867 |  |  |  |  |  |
Percentage of fully diluted share capital |  |  |  |  | 1.00% |  |  |  |  |  |
Second MSK Amendment | Memorial Sloan Kettering Cancer Center |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Milestone payments | $ 700 |  |  |  |  |  |  |  |  |  |
Stock issued during period shares conversion of debt in connection with licensing agreement |  |  |  | 13,815 |  |  |  |  |  |  |
Additional shares issued in connection with licensing agreement |  |  |  | 30,314 |  |  |  |  |  |  |
Research and development |  |  |  | $ 2,000 |  |  |  |  |  |  |
License agreement outstanding amount payable |  |  |  | $ 900 |  |  |  |  |  |  |
Maximum number of days to make payments | 60 days |  |  |  |  |  |  |  |  |  |
Second Amended and Restated Exclusive License Agreement | Memorial Sloan Kettering Cancer Center |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Shares issued under license agreement |  | 74,795 |  |  |  |  |  |  |  |  |
Additional shares issued in connection with licensing agreement |  | 7,700 |  |  |  |  |  |  |  |  |
Advaxis Collaboration Agreement |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Royalty payment, maximum rate |  |  |  |  |  |  |  | $ 1,000,000 |  |  |
Advaxis Collaboration Agreement | Maximum |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Non-refundable milestone payments |  |  | $ 108,000 |  |  |  |  |  |  |  |
Non-refundable sales milestone payments |  |  | $ 250,000 |  |  |  |  |  |  |  |
The University of Texas M. D. Anderson Cancer Center and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  |  | $ 3,800 |  |  |  |
Annual maintenance fee |  |  |  |  |  |  | $ 200 |  |  |  |
Chief Executive Officer Co-Founder | Memorial Sloan Kettering Cancer Center |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Shares issued under license agreement |  |  |  |  |  | 6,599 |  |  |  |  |
Co-founder | Memorial Sloan Kettering Cancer Center |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Shares issued under license agreement |  |  |  |  |  | 6,599 |  |  |  |  |

X
- Definition Additional Shares Issued In Connection With Licensing Agreement + References No definition available. + Details
Name: | gale_AdditionalSharesIssuedInConnectionWithLicensingAgreement
Namespace Prefix: | gale_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Annual Maintenance Fee + References No definition available. + Details
Name: | gale_AnnualMaintenanceFee
Namespace Prefix: | gale_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition License Agreement Expiration Term + References No definition available. + Details
Name: | gale_LicenseAgreementExpirationTerm
Namespace Prefix: | gale_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition License Agreement, Milestone Payments + References No definition available. + Details
Name: | gale_LicenseAgreementMilestonePayments
Namespace Prefix: | gale_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition License Agreement Outstanding Amount Payable + References No definition available. + Details
Name: | gale_LicenseAgreementOutstandingAmountPayable
Namespace Prefix: | gale_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License And Collaboration Agreements [Line Items] + References No definition available. + Details
Name: | gale_LicenseAndCollaborationAgreementsLineItems
Namespace Prefix: | gale_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Maximum Number Of Days To Make Payments + References No definition available. + Details
Name: | gale_MaximumNumberOfDaysToMakePayments
Namespace Prefix: | gale_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone Fee Payments Upon Commencement Of Clinical Trials + References No definition available. + Details
Name: | gale_MilestoneFeePaymentsUponCommencementOfClinicalTrials
Namespace Prefix: | gale_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Minimum Annual Royalty Payment + References No definition available. + Details
Name: | gale_MinimumAnnualRoyaltyPayment
Namespace Prefix: | gale_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Non-refundable Milestone Payments + References No definition available. + Details
Name: | gale_NonrefundableMilestonePayments
Namespace Prefix: | gale_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Non-refundable Sales Milestone Payments + References No definition available. + Details
Name: | gale_NonrefundableSalesMilestonePayments
Namespace Prefix: | gale_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage Of Fully Diluted Share Capital + References No definition available. + Details
Name: | gale_PercentageOfFullyDilutedShareCapital
Namespace Prefix: | gale_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research Funding Costs + References No definition available. + Details
Name: | gale_ResearchFundingCosts
Namespace Prefix: | gale_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Royalty Payment, Maximum Rate + References No definition available. + Details
Name: | gale_RoyaltyPaymentMaximumRate
Namespace Prefix: | gale_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Shares Issued Under License Agreement + References No definition available. + Details
Name: | gale_SharesIssuedUnderLicenseAgreement
Namespace Prefix: | gale_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Stock Issued During Period Shares Conversion Of Debt In Connection With Licensing Agreement + References No definition available. + Details
Name: | gale_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement
Namespace Prefix: | gale_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront License Fees + References No definition available. + Details
Name: | gale_UpfrontLicenseFees
Namespace Prefix: | gale_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=gale_MemorialSloanKetteringCancerCenterMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=gale_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gale_LicenseAmendmentWaiverAndShareIssuanceAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gale_SecondMSKAmendmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gale_SecondAmendedandRestatedExclusiveLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gale_AdvaxisCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gale_TheUniversityofTexasM.D.AndersonCancerCenterandTheHenryM.JacksonFoundationfortheAdvancementofMilitaryMedicineInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TitleOfIndividualAxis=gale_ChiefExecutiveOfficerCoFounderMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TitleOfIndividualAxis=gale_CofounderMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |